Sarepta Therapeutics (SRPT) Free Cash Flow (2010 - 2026)

Sarepta Therapeutics' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$204.8 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 67.35% year-over-year to -$204.8 million; the TTM figure through Mar 2026 stood at $114.9 million (up 116.52% YoY), while the FY2025 annual figure was -$307.5 million, up 10.3% from the prior year.
• Free Cash Flow was -$204.8 million for Q1 2026 at Sarepta Therapeutics, down from $127.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $229.5 million in Q2 2025 to a low of -$627.1 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$105.2 million across 5 years, with a median of -$100.4 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Free Cash Flow sank 218.27% in 2022, then surged 1713.64% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$100.4 million in 2022, then rose by 26.57% to -$73.7 million in 2023, then surged by 173.23% to $54.0 million in 2024, then jumped by 136.48% to $127.6 million in 2025, then sank by 260.45% to -$204.8 million in 2026.
• The last three Free Cash Flow figures came in at -$204.8 million (Q1 2026), $127.6 million (Q4 2025), and -$37.5 million (Q3 2025), per Business Quant data.